Revolution Medicines' daraxonrasib appears in two new pancreatic cancer trial registrations
Two Phase 1 studies combining daraxonrasib with other agents in pancreatic cancer were registered this week, one sponsored by Dana-Farber and one by ParVation Therapeutics.
Two registry entries this week involve daraxonrasib (RMC-6236), a RAS inhibitor associated with Revolution Medicines, in pancreatic cancer settings.
- Dana-Farber Cancer Institute registered a Phase 1 trial of daraxonrasib in resectable pancreatic ductal adenocarcinoma (NCT07898813), with Revolution Medicines and The Mark Foundation for Cancer Research as collaborators. The study is not yet recruiting1 and plans to enroll 30 participants over 24 months, with post-treatment follow-up at least every 6 months for up to 5 years.1 Patients will receive pre-surgery daraxonrasib treatment, surgery, adjuvant chemotherapy with or without radiation, optional adjuvant daraxonrasib, and follow-up.1
- ParVation Therapeutics registered a Phase 1 dose-escalation and expansion trial combining its investigational drug SNV1521 with daraxonrasib in locally advanced unresectable or metastatic pancreatic cancer (NCT07756281), listing Revolution Medicines as a collaborator. The study is recruiting2, with one site in Houston, Texas2 and estimated enrollment of 40 participants, aiming to find safe and tolerable doses through safety and tolerability of SNV1521 plus daraxonrasib, measured by treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities, used to identify doses suitable for further study2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.